Bernie Sanders wants HHS to look in­to the price of Ei­sai's new­ly ap­proved Alzheimer's drug

Sen­ate Health Com­mit­tee Chair Bernie Sanders (I-VT) is hav­ing no qualms about his pur­suit of low­er­ing drug prices.

First, he went af­ter the top in­sulin man­u­fac­tur­ers with a grilling, and then he pledged to block Pres­i­dent Joe Biden’s NIH di­rec­tor nom­i­nee Mon­i­ca Bertag­nol­li if the ad­min­is­tra­tion doesn’t do more to low­er drug prices (even af­ter the In­fla­tion Re­duc­tion Act passed). And now he’s call­ing on HHS Sec­re­tary Xavier Be­cer­ra to take a clos­er look at the price of Ei­sai and Bio­gen’s new, ful­ly ap­proved Alzheimer’s drug Leqem­bi (lecanemab).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER